Immunocellular Therapeutics LTD (IMUC) financial statements (2020 and earlier)

Company profile

Business Address 30721 RUSSELL RANCH ROAD
WESTLAKE VILLAGE, CA 91362
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments71123232826
Cash and cash equivalents71123232826
Prepaid expense 11  
Prepaid expense and other current assets1
Other current assets01111
Total current assets:71325242827
Noncurrent Assets
Property, plant and equipment000000
Prepaid expense 11  
Deposits noncurrent assets 24  0
Deferred costs  00  
Other noncurrent assets   10
Other undisclosed noncurrent assets 0    
Total noncurrent assets:036110
TOTAL ASSETS:71730252927
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities232111
Accounts payable211011
Accrued liabilities010100
Employee-related liabilities011000
Total current liabilities:232111
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 86   
Total noncurrent liabilities: 86   
Total liabilities:2118111
Stockholders' equity
Stockholders' equity attributable to parent, including:5622232623
Common stock000000
Additional paid in capital12110296857866
Accumulated deficit(116)(96)(74)(61)(52)(43)
Warrants and rights outstanding   113
Other undisclosed stockholders' equity attributable to parent   (1)(1)(3)
Total stockholders' equity:5622232623
Other undisclosed liabilities and equity   113
TOTAL LIABILITIES AND EQUITY:71730252927

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Gross profit:    (1)(0)
Operating expenses(21)(24)(16)(10)(9)(12)
Operating loss:(21)(24)(16)(10)(9)(12)
Nonoperating income (expense)
(Investment Income, Nonoperating)
04311(2)
Interest and debt expense7(1)(0)   
Other undisclosed loss from continuing operations before equity method investments, income taxes     (0)
Loss from continuing operations before equity method investments, income taxes:(14)(22)(13)(9)(9)(14)
Other undisclosed loss from continuing operations before income taxes (0)(0)(0)  
Net loss attributable to parent:(14)(22)(13)(9)(9)(14)
Other undisclosed net loss available to common stockholders, basic(3)     
Net loss available to common stockholders, diluted:(18)(22)(13)(9)(9)(14)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(14)(22)(13)(9)(9)(14)
Comprehensive loss, net of tax, attributable to parent:(14)(22)(13)(9)(9)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: